These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30688711)

  • 1. Lactulose Management of Minimal Hepatic Encephalopathy: A Systematic Review.
    Zucker DM; Redulla R
    Gastroenterol Nurs; 2019; 42(1):84-94. PubMed ID: 30688711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should We Treat Minimal/Covert Hepatic Encephalopathy, and with What?
    Henderson PK; Herrera JL
    Clin Liver Dis; 2015 Aug; 19(3):487-95. PubMed ID: 26195203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disaccharides in the treatment of hepatic encephalopathy.
    Sharma P; Sharma BC
    Metab Brain Dis; 2013 Jun; 28(2):313-20. PubMed ID: 23456517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of hepatic encephalopathy in the hospital.
    Leise MD; Poterucha JJ; Kamath PS; Kim WR
    Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probiotics for patients with hepatic encephalopathy.
    McGee RG; Bakens A; Wiley K; Riordan SM; Webster AC
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008716. PubMed ID: 22071855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study.
    Poo JL; Góngora J; Sánchez-Avila F; Aguilar-Castillo S; García-Ramos G; Fernández-Zertuche M; Rodríguez-Fragoso L; Uribe M
    Ann Hepatol; 2006; 5(4):281-8. PubMed ID: 17151582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.
    Mittal VV; Sharma BC; Sharma P; Sarin SK
    Eur J Gastroenterol Hepatol; 2011 Aug; 23(8):725-32. PubMed ID: 21646910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Efficacy of Treatment Options for Minimal Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis.
    Dhiman RK; Thumburu KK; Verma N; Chopra M; Rathi S; Dutta U; Singal AK; Taneja S; Duseja A; Singh M
    Clin Gastroenterol Hepatol; 2020 Apr; 18(4):800-812.e25. PubMed ID: 31476436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic Management of Hepatic Encephalopathy.
    Khalessi A; Pyrsopoulos NT
    Clin Liver Dis; 2024 May; 28(2):287-296. PubMed ID: 38548440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Gluud LL; Vilstrup H; Morgan MY
    Cochrane Database Syst Rev; 2016 Apr; 4():CD003044. PubMed ID: 27089005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonabsorbable disaccharides for hepatic encephalopathy.
    Als-Nielsen B; Gluud LL; Gluud C
    Cochrane Database Syst Rev; 2004; (2):CD003044. PubMed ID: 15106187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy.
    Agrawal A; Sharma BC; Sharma P; Sarin SK
    Am J Gastroenterol; 2012 Jul; 107(7):1043-50. PubMed ID: 22710579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylaxis of hepatic encephalopathy: current and future drug targets.
    Maharshi S; Sharma BC
    Hepatol Int; 2024 Aug; 18(4):1096-1109. PubMed ID: 38492132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.
    Prakash RK; Kanna S; Mullen KD
    Clin Ther; 2013 Sep; 35(9):1458-73. PubMed ID: 23972578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: A multicenter, randomized controlled trial.
    Wang JY; Bajaj JS; Wang JB; Shang J; Zhou XM; Guo XL; Zhu X; Meng LN; Jiang HX; Mi YQ; Xu JM; Yang JH; Wang BS; Zhang NP
    J Dig Dis; 2019 Oct; 20(10):547-556. PubMed ID: 31448533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal hepatic encephalopathy.
    Sharma P
    J Assoc Physicians India; 2009 Nov; 57():760-3. PubMed ID: 20329443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy.
    Sharma P; Sharma BC; Puri V; Sarin SK
    Eur J Gastroenterol Hepatol; 2008 Jun; 20(6):506-11. PubMed ID: 18467909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes.
    Rahimi RS; Brown KA; Flamm SL; Brown RS
    Am J Med; 2021 Nov; 134(11):1330-1338. PubMed ID: 34242619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on the Therapeutic Management of Hepatic Encephalopathy.
    Kornerup LS; Gluud LL; Vilstrup H; Dam G
    Curr Gastroenterol Rep; 2018 Apr; 20(5):21. PubMed ID: 29644492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevention and treatment of hepatic encephalopathy].
    Sivolap YP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):144-147. PubMed ID: 29171503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.